Skip to Main Content

Pharmacology and Chemical Biology Seminar Series

Pharmacology & Chemical Biology Seminar Series
10/6/2022 - 12:00 PM-1:00 PM

Yuwei Jiang, PhD 
Assistant Professor
Department of Physiology and Biophysics
University of Illinois at Chicago

The induction of thermogenic beige adipocytes in white adipose tissue is a promising avenue for the treatment of obesity and Type 2 diabetes. In this seminar, I will discuss the cell origins of beige adipocytes, and then present a novel mechanism regulating beige adipocyte formation and maintenance that could be developed therapeutically.

 

Pharmacology & Chemical Biology Seminar Series
10/20/2022 - 12:00 PM-1:00 PM

Prof. Dr. Andreas Bock 
Medical Faculty
Leipzig University
Rudolf-Boehm-Institute of Pharmacology and Toxicology
 

G protein-coupled receptors (GPCRs) form the largest family of cell membrane receptors and modulate almost any (patho)physiological process in humans. GPCR signaling involves activation of distinct G-protein families, modulation of multiple intracellular second messengers, such as cAMP, and activation of kinases. Therefore, GPCRs orchestrate overwhelmingly complex intracellular signaling networks that are capable of precisely relaying signals in space and time to exert a myriad of specific cell functions. 
To ensure signaling specificity, GPCRs and their downstream signals are compartmentalized in very small regions in the cell that are called nanodomains. In my talk, I will introduce the concept of signaling compartmentation and highlight our recent work on cAMP nanodomains. Disruption of GPCR signaling networks can lead to noncommunicable diseases such as heart failure and cancer, and I will briefly discuss potential roles of nanodomain signaling in such diseases.  

 

Pharmacology & Chemical Biology Seminar Series
11/3/2022 - 12:00 PM-1:00 PM

Mustafa Sahin, MD, PhD  
Professor, Neurology
Harvard Medical School
 

Dr. Sahin will discuss the role of TSC1 and TSC2 proteins in regulating various neuronal functions through mTOR in cell culture and animal models and the implications of the basic research for developing therapies for clinical indications.
 

Pharmacology & Chemical Biology Seminar Series
11/10/2022 - 12:00 PM-1:00 PM

Martha Cyert, PhD 
Chair, Department of Biology
Stanford University

We are systematically discovering signaling pathways for Calcineurin, the calcium/calmodulin regulated phosphatase and target of immunosuppressants FK506 and Cyclosporin A. Using in silico and experimental approaches we are demonstrating new roles for calcineurin in Notch signaling, phosphoinositide signaling, at the nuclear pore and at centrosomes and cilia.
 

Pharmacology & Chemical Biology Seminar Series
11/17/2022 - 12:00 PM-1:00 PM

Jennifer Adibi, ScD, MPH
Assistant Professor
Department of Epidemiology
University of Pittsburgh Graduate School of Public Health


Pharmacology & Chemical Biology Seminar Series
12/1/2022 - 12:00 PM-1:00 PM

Sankari Nagarajan, PhD  
Lecturer in Chromatin Biology
University of Manchester
 


Pharmacology & Chemical Biology Seminar Series
12/8/2022 - 12:00 PM-1:00 PM

Ji Sun, PhD 
Assistant Member
St. Jude Children’s Research Hospital

Gain-of-function mutations in LRRK2 lead to Parkinson’s Disease (PD); therefore, LRRK2 inhibitors hold great potential for PD treatment. In this seminar, Dr. Sun will discuss the structure-function relationship of LRRK2, focusing on the following questions. 1) What is the architecture of LRRK2, a 286-kDa multi-domain protein? 2)  How is LRRK2 recruited to membrane surface by Rab GTPase? 3) How is LRRK2 activated upon membrane recruitment. And 4) What can we learn about LRRK2 PD mutations to guide future drug development?  
 

Pharmacology & Chemical Biology Seminar Series
12/15/2022 - 12:00 PM-1:00 PM

Mikel Garcia-Marcos, PhD 
Professor
Department of Biochemistry
Boston University School of Medicine
 

Our research program aims to understand the mechanisms and consequences cell communication via heterotrimeric G-proteins (Gαβγ) because they represent major intracellular hubs of signaling with very direct biomedical relevance. To achieve this goal, we use a wide range of approaches (biochemistry, cell biology, genetics, drug screening/ development) and experimental systems (purified proteins, cultured cells, model organisms) in combination with the development of novel tools (biosensors, chemogenetics, optogenetics). Our ongoing efforts have direct implications in cancer, embryonic development defects, and neurological disorders.